Delivery Order SPE2DB20D2014-SPE2DB25FD14T
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 10, 2025, for the supply of Otezla 30 mg tablets (60-count units) valued at $16,575.87 under a firm fixed-price arrangement. The contract is non-competitive with no set-aside designation and requires completion by September 11, 2025. This delivery order is issued against AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a comprehensive $999,999,999...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 18, 2025, for the supply of Otezla 30 mg tablets (60-count units) with a ceiling value of $30,038.24. This is a firm fixed price delivery order with no set-aside designation, indicating competitive award. The order is set for ultimate completion on September 19, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order valued at $18,874.86 to AmerisourceBergen Drug Corp for the supply of Otezla 30 mg tablets (60-count units) on August 20, 2025, with a completion date of August 21, 2025. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The place of...
- The Defense Logistics Agency awarded a delivery order valued at $7,288.52 to AmerisourceBergen Drug Corp for the supply of Otezla 30 mg tablets (60-count units) on April 24, 2025, with an ultimate completion date of April 25, 2025. This competitive award, issued under firm fixed-price terms with no set-aside designation, represents a child delivery order against AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The contract's place of performance is...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $1,311.62 on September 15, 2025, for Otezla 20 mg tablets (60-count supply). This is a firm fixed-price, non-competitive delivery order with an ultimate completion date of September 16, 2025, and will be performed at the contractor's corporate office in Conshohocken, Pennsylvania. Otezla is a prescription medication used primarily to treat psoriasis, psoriatic arthritis, and behçet's disease. This...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 2, 2025, for the supply of Otezla 30 mg tablets in quantities of 60 units, with a ceiling value of $2,623.24. This non-set-aside, firm fixed-price delivery order is scheduled for ultimate completion on September 3, 2025, with performance taking place at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical federal...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Otezla 30 mg tablets (60-count units) with a contract ceiling value of $29,588.62. This firm fixed-price delivery order, which is expected to conclude by August 15, 2025, represents a competitively awarded, non-set-aside contract with performance directed to AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The award demonstrates the contractor's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of Otezla 30 mg tablets (60-count packaging) with a ceiling value of $13,807.38. This is a firm fixed price delivery order with no set-aside designation, indicating competitive award to this qualified pharmaceutical vendor. The order is scheduled for completion by September 9, 2025, and will be fulfilled from the contractor's location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $11,993.83 to AmerisourceBergen Drug Corp for the supply of Otezla 30 mg tablets (60-count packaging) on July 22, 2025, with an ultimate completion date of July 23, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform this work at its corporate office location....
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 19, 2025, for the supply of Otezla 30 mg tablets in a 60-count quantity. This $12,417.30 firm fixed-price delivery order, which is not set-aside, is scheduled for completion by September 22, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract...
- SPE2DB20D2014Indefinite Delivery Contract
- SPE2DB20D2014-SPE2DB25FD14TDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 26, 2025, for the supply of Otezla 30 mg tablets (quantity: 60 units) with a ceiling value of $15,535.75. This is a firm fixed-price delivery order with an ultimate completion date of September 29, 2025, utilizing no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement, particularly supporting military and veteran healthcare systems through the Defense Logistics Agency's Medical Supply Chain. This delivery order represents a task order under AmerisourceBergen's broader Indefinite Delivery Contract with DLA Troop Support Medical (designated SPE2DX), valued at $999,999,999.00 and extending through December 2026. The parent IDC serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply an extensive range of pharmaceutical products and medical supplies to support military healthcare programs worldwide. Otezla (apremilast) is a prescription medication primarily used for treating plaque psoriasis, psoriatic arthritis, and Behçet's disease-related oral ulcers, consistent with AmerisourceBergen's portfolio of specialty medications supporting Defense Health Agency requirements and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $15.5k | 9/26/25 |